Kestra Medical Technologies (NASDAQ:KMTS) Sets New 1-Year Low - What's Next?

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $13.25 and last traded at $14.26, with a volume of 191012 shares. The stock had previously closed at $16.29.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on KMTS. The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $24.00 to $23.00 and set a "neutral" rating for the company in a report on Wednesday, April 16th. Piper Sandler began coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an "overweight" rating and a $27.00 price objective for the company. Bank of America began coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set a "buy" rating and a $30.00 price objective for the company. Wolfe Research began coverage on Kestra Medical Technologies in a report on Monday, March 31st. They set an "outperform" rating and a $29.00 price objective for the company. Finally, Wells Fargo & Company dropped their price objective on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $27.33.

Kestra Medical Technologies Stock Up 7.2%

The company has a fifty day simple moving average of $19.14.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its quarterly earnings results on Monday, April 14th. The company reported ($1.25) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same period in the previous year, the company earned ($1.18) earnings per share.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Caas Capital Management LP purchased a new stake in Kestra Medical Technologies in the first quarter valued at about $1,470,000. Brown Advisory Inc. purchased a new stake in Kestra Medical Technologies in the first quarter valued at about $13,716,000. Eventide Asset Management LLC purchased a new stake in Kestra Medical Technologies in the first quarter valued at about $6,853,000. Russell Investments Group Ltd. acquired a new position in shares of Kestra Medical Technologies in the first quarter valued at about $457,000. Finally, Armistice Capital LLC acquired a new position in shares of Kestra Medical Technologies in the first quarter valued at about $312,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.